Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The impact of ESAs in lower-risk MDS

Hege Garelius • 9 Jun 2022
EHA 2022
Myelodysplastic Syndromes ESA

Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, outlines the results of a study investigating the impact of erythropoietin stimulating agents (ESAs) in lower-risk myelodysplastic syndromes (MDS). The study showed that patients receiving ESAs prior to transfusions had an improved overall survival (OS), and that patients who were transfused had a worse quality of life (QoL) than patients who were not. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Hege Garelius

0:58
Risk stratification in MDS
Hege Garelius • 9 Jun 2022
1:34
Perspectives on the management of low and high-risk MDS
Hege Garelius • 9 Jun 2022
0:33
Unmet needs in MDS: treating relapse after alloHSCT & TP53-mutated disease
Hege Garelius • 9 Jun 2022

Related Videos

2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals